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Abstract 
One theory of why some pathogens are virulent (i.e. they damage their host) is 
that they need to extract resources from their host in order to compete for transmission 
to new hosts, and resource extraction can damage the host.  Here we describe our 
studies in malaria that test this idea.  We go on to show that host immunity can 
exacerbate selection for virulence and therefore that vaccines that reduce pathogen 
replication may select for more virulent pathogens, eroding the benefits of vaccination 
and putting the unvaccinated at greater risk.  We suggest that in disease contexts 
where wild-type parasites can be transmitted through vaccinated hosts, evolutionary 
outcomes need to be considered. 
 
1. An evolutionary hypothesis for pathogen virulence 
 
Why are pathogens virulent
1
? Why would they run the risk of killing their host 
when, in doing so, they lose their ongoing source of transmission to new hosts?   
Some evolutionary biologists believe that the answer to this question will make it 
possible to design vaccines and other control measures that, in the event of eradication 
being impossible, drive the pathogen towards lower virulence (Williams and Nesse, 
1991; Dieckmann et al., 2002).   
One answer to this question is that virulence is a mistake by the pathogen – an 
ultimately maladaptative outcome that occasionally happens when a pathogen 
accidentally ends up in an abnormal host environment, or when a virulent mutant has 
a transient competitive advantage within a host (‘short-sighted, or dead-end 
evolution’) (Levin and Bull, 1994).  An alternative (but not mutually exclusive 
(Frank, 1996)) idea is that the level of pathogen virulence observed in nature is a well-
adapted outcome of both positive and negative selective forces acting on virulence.  
Under this hypothesis, it is reckoned that to balance the fitness cost to the pathogen of 
host death, there must also be a virulence-related advantage to its fitness.  This is the 
so-called ‘virulence trade-off hypothesis’. 
                                                          
1
 Throughout this paper, we strictly define virulence as the fitness cost that the parasite causes the host.  
This may be through mortality, or morbidity-related reduction in fertility or fecundity.  We sometimes 
use morbidity as a surrogate measure of virulence. 
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Of all the explanations for virulence, the trade-off hypothesis has received 
most attention and a large body of theory has been derived from it.  Yet it is poorly 
supported by data.   Here we describe our studies in malaria parasites, the causative 
agents of a disease of global importance, in which we have comprehensively explored 
the trade-off hypothesis.  We begin by summarising our experimental tests in a 
laboratory mouse-malaria system of the assumptions underlying the trade-off theory.  
We then ask whether the rodent data are relevant to malaria parasites in their human 
setting.  Next, we use the trade-off theory to predict what the impact might be on the 
evolution of the pathogen’s virulence if malaria vaccines went into widespread use.  
Finally, we summarise an experimental evolution study to test our prediction that 
enhanced immunity would select for more virulent parasites.  Together, this work has 
led us to a deeper understanding of why malaria still kills its host despite millenia of 
coevolution, and what might happen when disease control campaigns change the level 
of population immunity, e.g., enhance it using vaccines, or reduce it using bednets and 
vector control.    
 
1.1. The trade-off hypothesis and its assumptions 
 
Under the trade-off hypothesis, it is assumed that there are both fitness 
benefits and costs associated with virulence.  The cost is assumed to be host death 
because, for most pathogens, dead hosts do not transmit.  The benefits associated with 
virulence are assumed to be production of more transmission forms per unit time, 
and/or increased persistence in a live host. However, the benefits of higher 
transmissibility and persistence only accrue if the host survives: if it dies, transmission 
immediately ceases, thereby directly reducing the pathogen’s fitness.   The pathogen 
is thus playing a perilous game, attempting to maximise transmissibility and infection 
length while also keeping its host alive. Pathogens with the highest fitness are those 
with an intermediate level of virulence which balances these opposing contributions to 
fitness (Fig. 1).   
 
1.2.  Evidence from myxomatosis 
 
Although the trade-off idea was mooted by medical epidemiologists early in 
the 20
th
 century (Topley, 1919) and much later by theoretical biologists  (Levin and 
Pimentel, 1981; Bremermann and Pickering, 1983), it was Anderson and May’s 
(1982) analysis of the principle using a real-life example which really focussed 
thinking. The myxoma virus was extremely virulent when released into rabbit 
populations in Australia and Britain in the early 1950’s, but over the next decade, the 
virus evolved to an intermediate and stable level of virulence (Fenner, 1953; Fenner et 
al., 1957). Using data from Fenner and colleagues  (Fenner and Ratcliffe, 1965) which 
showed that viral strains that caused more host death were also those capable of 
generating longer infections (Fig. 2a), Anderson and May (1982) showed that 
maximum fitness of the virus occurred at an intermediate level of virulence.  This was 
because the more virulent strains produced longer infections in the absence of host 
death, but death occurred more often in these strains. In their analysis they assumed 
that transmissibility was constant, i.e., the trade-off was generated exclusively by the 
relationship between virulence and infection length.  Similarly, using the data of 
Mead-Briggs and Vaughan (1975) which show higher transmissibility in the more 
virulent strains (except at very high levels, Fig. 2b),  Massad (1987) showed that 
maximum pathogen fitness was reached at intermediate levels of virulence.  Thus 
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either the virulence-infection length relationship or the virulence-transmissibility 
relationship, or the combination of the two (Fig. 2c) could explain the observed 





 Inspired by the myxomatosis example, and conscious of the lack of relevant 
data in medically important pathogens, we set out to explore whether this trade-off 
was operating in a major pathogen of humans - Plasmodium.  The causative agent of 
the most pathogenic form of human malaria, Plasmodium falciparum, replicates 
rapidly within its host, as do many viral, bacterial, and other protozoal pathogens.  
Unlike viruses and bacteria, however, the malaria parasite has separate transmission 
stages called gametocytes.  Gametocytes, the sexual form of the parasite, are 
differentiated from the asexual, replicating blood-stage forms.  Gametocytes do not 
themselves replicate, and are seen at low densities in the bloodstream.  But as they are 
the only forms that survive in the mosquito vector, the pathogen must produce them in 
order to be transmitted. Moreover, mosquitoes only feed on live hosts.  In hosts that 
survive, immunity clears parasites. Thus, on the face of it, the necessary ingredients 
for the trade-off model are present: the most evolutionarily successful parasite is one 
which maximises transmission stage production while avoiding host death and 
immune clearance.   
 
2.1.  Data from mouse malaria 
 
We began by testing the assumptions of the trade-off hypothesis using the 
mouse malaria model, P. chabaudi, as an experimental model.  Using parasite clones 
obtained from their natural host in the wild (Beale et al., 1978) and then passaged for 
a short period in laboratory mice, we infected groups of inbred mice and measured the 
transmissibility, virulence and persistence of these clones and the genetic (i.e., across-
clone) relationships among these traits (Mackinnon and Read, 1999a, 2003; Ferguson 
et al., 2003).  Transmissibility was measured as the number of gametocytes per unit 
time: it was further measured as the proportion of mosquitoes that became infected 
after being allowed to take a blood-meal from an infected mouse.  Persistence was 
measured by the time it took to clear an infection to below a threshold value. 
Virulence was, for ethical and logistical reasons, measured not by mortality but by 
morbidity, viz., maximum level of anaemia or weight loss experienced by the host 
during the infection: these are positive indicators of the probability of host death.  We 
also measured the maximum asexual parasite density reached during the infection as 
an indicator of the parasite’s degree of exploitation of the host.  In malaria, this is a 
useful trait through which virulence-transmission-persistence relationships (hereafter 
V-T-P) can be examined since parasite density is a major underlying cause of all three 
traits: asexual replication is directly responsible for the disease pathology, the 
production of gametocytes, and for maintenance of the infection. 
Our experiments showed that clones that had higher levels of virulence also 
had higher transmissibility (both production of gametocytes and infectivity to 
mosquitoes) and cleared their infections more slowly in the absence of host death 
(Fig. 3) (Mackinnon and Read, 1999a, b, 2003; Ferguson et al., 2003).  Virulent 
parasites were also those that generated highest parasite densities and thus exploited 
more of the host’s resources (red cells). Thus the V-T-P relationships assumed by the 
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trade-off hypothesis, and the parasite genetic basis for them, were supported in this 
experimental model.  Furthermore, if the host died, the total amount of gametocytes 
produced during the infection (i.e., the potential transmission) was less than if the host 
lived (Fig. 3e) thus demonstrating a clear cost of host mortality to the parasite’s 
fitness (Mackinnon et al., 2002). This result, however, was not repeated in a similar 
study (Ferguson et al., 2003) despite similar levels of mortality and gametocyte 
production in both experiments.  Further and larger experiments are required to 
determine the magnitude of the cost of host death to parasite fitness.  The findings 
described above were also broadly supported, at least at the phenotypic level, in 
another experimental system, the avian malaria, P. gallinaceum infecting chickens 
(Paul et al., 2004). 
We found the V-T-P relationships  also to be positive when measured in 
different host genotypes (Mackinnon et al., 2002; Grech et al., 2006), host sexes 
(Mackinnon and Read, 2004a), after serial passage (Mackinnon and Read, 1999b,  
2004a, Mackinnon et al., 2002), after mosquito passage (Mackinnon and Read, 2004a, 
2005) and, importantly (see below), in hosts with different  levels of acquired 
immunity (Mackinnon and Read, 2003, 2004a). Thus clones that were genetically 
more virulent, transmissible and persistent were consistently so, across a range of 
extrinsic, host-derived factors. 
In nature, malaria infections are frequently composed of several genetically 
distinct strains of parasites.  This introduces into the relatively simple scenario 
described above the question of whether the more virulent parasites are still more 
productive (i.e., fit)  than their less virulent counterparts when they are competing in 
the same host. Theoreticians have envisaged a range of possible outcomes of this 
competition, and hence effects on virulence evolution (reviewed in  Read and Taylor, 
2001).  Experimental data using the P. chabaudi model, generally indicate that more 
virulent clones have a competitive advantage: they are able to competitively suppress 
or even exclude less virulent clones during the acute phase of mixed-clone infections 
(De Roode et al., 2005a; Bell et al., 2006).  The competitive outcome is reflected in 
relative gametocyte production of the two competing strains (Wargo et al., in review) 
and hence transmission to mosquitoes  (De Roode et al., 2005a, b).  This result 
appears to be qualitatively robust to host genotype (De Roode et al., 2004) and host 
immune status  (Räberg et al., 2006; Grech et al., submitted). Thus, the transmission 
and persistence advantages of virulence accrue even in mixed infections. 
Important to the argument that follows, in the mouse model, immunity acted to 
reduce all three traits – transmissibility, virulence, and persistence - in line with that 
expected from the relationships among these traits in naïve hosts.  Also, clones 
broadly retained their rankings for virulence and other traits across naïve and immune 
hosts (Fig. 3). In other words, the parasite lines that replicated well, transmitted faster, 
lasted longer and caused more morbidity when infecting naïve hosts, also did so in 
semi-immune hosts, but just at a lower level.   
 
2.2. Data from human malaria 
 
Do the relationships we observed in mice apply to human malaria?  
Unfortunately there are not adequate data to properly assess this, and there probably 
never will be.  This is because we cannot, for both logistical and ethical reasons, 
measure the virulence of a panel of distinct human malaria strains in groups of 
individual hosts to determine the human parasite’s genetic relationships in V-T-P 
traits.  However, two types of data which represent the phenotypic relationships 
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among these traits are qualitatively consistent with the positive genetic relationships 
we observed in the laboratory mouse.  
 The first type of data comes from a longitudinal cross-sectional population 
survey in Nigeria (the Garki project) (Molineaux and Gramiccia, 1980).  The data 
from this are summarised in the form of plots of average values for each age-class of 
V, T and P (measured by mortality rates, average gametocyte density while infected, 
duration of infection for each new infection) against average asexual densities, an 
indicator of the degree of host exploitation by the parasite (Fig. 4). Across the age-
spectrum, all three traits increased with exploitation levels, consistent with those 
assumed by the trade-off hypothesis and observed in rodent and avian malarias. 
However, two important caveats apply to these human malaria data regarding 
their relevance to the trade-off hypothesis. The first is that parasite genetics is 
averaged out in these relationships (each age-group is assumed to be infected by the 
whole range of parasite genotypes in the population).  Second, the observed 
relationships are undoubtedly driven by age-acquired immunity. Thus these curves, 
tight as they are, do not directly yield the parasite’s genetically encoded fitness 
benefits and costs of virulence as assumed by the model (Fig. 1), and seen in 
myxomatosis (Fig. 2) and rodent malaria (Fig. 3).  However, the Garki data are 
certainly not inconsistent with the model.  
A second source of data on V-T-P relationships is the series of infections of 
human patients with P. falciparum malaria in order to treat their neurosyphilis.   
Several laboratory-maintained strains were used to treat hundreds of patients, and 
their courses of asexual parasite densities, gametocyte densities, infection lengths, and 
morbidity (fever) were recorded for each infection for as long as 18 months, thus 
giving data relevant to V-T-P relationships (Collins and Jeffery, 1999,2003).  It was 
found that infections among malaria-naïve patients that reached higher maximum 
parasite densities, or had faster growth rates during the early stage of the infection, 
also persisted for longer, and caused higher levels of morbidity than infections that 
reached lower maximum densities (Mackinnon, in prep). However, as for the field 
studies described above, because few parasite strains were used, these relationships 
can not be assigned to parasite genetics.  Thus we still do not have a basis on which to 
critically evaluate the assumptions of the trade-off model for human malaria.   
It must also be noted, however, that there are various pieces of evidence to 
indicate the potential for virulence evolution in human malaria in response to 
changing selection pressures. These are as follows: there appears to be a parasite 
genetic basis to virulence, replication rate and perhaps transmissibility in P. 
falciparum (reviewed in  Mackinnon and Read, 2004b); there is some variability in 
virulence maintained in nature (Gupta et al., 1994; Bull et al., 1999); and there 
appears to be a link between intrinsic replication rate and virulence in P. falciparum 
(Chotivanich et al., 2000) (but see  Deans et al., 2006).  At the same time we 
recognise that there are many environmental and genetic factors relating to both the 
vertebrate and mosquito hosts that contribute much variability to the V-T-P 
relationships in human malaria.  What matters, however, to the direction of virulence 
evolution is whether on average they are qualitatively similar to that assumed by the 
theory (Fig. 1). 
Our experimental work with P. chabaudi clearly demonstrates fitness benefits 
to virulence (transmissibility, persistence and competitive ability). These are thus 
factors that promote the evolution of increased virulence. What factors balance these, 
preventing the evolution of extremely virulent malaria?  The trade-off model 
envisages the balancing selective pressure to arise through host death.  But in the 
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field, the majority of malaria infections do not end in death. Determining what the 
case fatality rate is for malaria in endemic regions is difficult, so that estimates are 
controversial, but the probability of a single infection leading to death is certainly less 
than 10% and probably less than 1%, perhaps even <0.1% (Snow et al., 1999). Is such 
a low risk of death a sufficient cost of virulence to offset the fitness benefits we have 
seen? To work this out definitively, we would need to determine both the transmission 
benefits and transmission costs associated with higher death rates.  The population-
wide case fatality rate is not a good indicator of whether evolution of high virulence is 
being constrained by host death because it does not directly reflect these transmission 
gains and losses.  We would also need to take account of the variable amount of 
transmission from hosts with different levels of immunity. The optimum virulence at 
endemic equilibrium will not only depend on the shape of the virulence-fitness curve, 
but also on the parasite’s productivity (total transmission per infection lifetime) in 
each host type, and the abundance of each host type  (Dushoff, 1996; Regoes et al., 
2000; Gandon et al., 2001; Ganusov et al., 2002; Gandon, 2004).   
Data from the Garki project help to illustrate this last point.  Mortality rates are 
much higher in children, especially very young children, where they are two orders of 
magnitude higher than in adults (Fig 4c).  But it is also these younger (non-immune) 
groups that have the capacity to generate high gametocyte densities and persistent 
infections (Figs. 4a,b).  As Fig. 5 shows, this is the group that contributes most (20-
fold more than adults) to the parasite’s total transmission population, but also suffers 
the highest virulence and hence cost to transmission. Thus one might plausibly argue 
that it is the youngest children that have the most  ‘weight’ in determining the 
optimum level of virulence for the population. Moreover, it follows from the trade-off 
view that more virulent parasites could be maintained in the population by semi-
immune, transmitting adults, which they are less likely to kill.  Such parasites would 
pay a cost when they kill very young children.  Or, if looked at from the host’s point 
of view, the young children are paying the cost of adult immunity. This raises the 
question we now turn to: how will virulence evolution be altered when a greater 
proportion of the parasites are facing immune hosts, as would occur following 
widespread vaccination? 
 
3. The vaccination theory 
 
3.1.  The principle 
 
Before going on to describe the principle of our vaccination theory, we define 
two terms which will be used in the following discussion: these are intrinsic and 
realised virulence.  Realised virulence is the virulence that would be observed in a 
host at a given level (any level) of host defence. Intrinsic virulence is the virulence 
that would be observed if the parasite was infecting a naïve host: in a better defended 
host, for the same level of intrinsic virulence, the realised virulence would be lower.  
We need intrinsic virulence as a common reference in order to study changes in 
virulence in populations of hosts with mixed levels of defence. 
If there are intrinsic biological links between the V-T-P traits that cover the 
whole spectrum of host defence, the parasite in semi-immune hosts is subject to the 
same fitness trade-off as proposed for naïve hosts (Fig. 1).  The only difference is that 
the realised cost of virulence, host death, is lower in immune hosts than the realised 
cost in naïve hosts. This means that in semi-immune hosts, the parasite, in order to 
achieve higher effective replication rate, transmission and persistence, can afford a 
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higher level of intrinsic virulence without paying the cost of host death. In other 
words, parasites with high virulence can ‘get away with it’ in a semi-immune host.  
Therefore intrinsic virulence should evolve to be higher in populations with higher 
levels of immunity than in populations of naïve hosts (Read, 1994; Frank, 1996; Van 
Baalen, 1998; Gandon and Michalakis, 2000; Gandon et al., 2001; Ganusov and 
Antia, 2006).  In our model the amount by which it does so in a population consisting 
entirely of immune hosts, relative to that for a completely naïve population, is the 
same amount by which immunity decreases realised virulence over intrinsic virulence.  
This principle is illustrated in Fig. 6.  Note that under the assumptions of our model, 
this principle would apply to any pathogen where the trade-off holds, and for any 
form of host resistance (genetically innate, naturally acquired, or vaccine-induced) 
that operates to reduce parasite virulence, e.g., via reduced parasite growth rates or 
anti-toxin effects (Gandon et al., 2001, 2002).  
 
3.2. Application to asexual stage vaccines in malaria 
 
The data from mice and humans strongly indicate that in malaria the common 
factor underlying the V-T-P relationships is asexual parasite density.  We reasoned, 
therefore, that any control measures that brought about a reduction in asexual parasite 
densities would bring about evolution for increased intrinsic virulence because of its 
consequences to transmissibility, persistence and host mortality (Gandon et al., 2001).  
This would include anti-asexual stage vaccines and drugs which were imperfect or 
‘leaky’, i.e. that did not completely prevent or clear infections, respectively.  If this 
evolution were to happen, the unprotected (e.g. unvaccinated) people in the 
population would then be exposed to a more virulent parasite and their risk of death 
would be higher than before. 
On the other hand, it might be argued, the vaccine, if used widely, would 
protect many more people from disease so that the population-wide reduction in 
mortality may well outweigh the increased mortality among the unvaccinated few.  
Further, the vaccine would reduce the force of infection through its effect on 
transmissibility, thus conferring an extra benefit to the population through herd 
immunity (Anderson and May, 1985).  This would further relieve the natural selection 
pressure on the parasite’s virulence from naturally acquired immunity.  It would also 
reduce the incidence of multiple infections: all of these effects are generally 
considered to be beneficial. Thus, as is often the case in vaccination programmes, 
even without evolution, the benefits to the majority of the population have to be 
weighed against the risk to a few individuals. 
Therefore, to determine the benefit to the whole population of vaccination 
allowing for an evolutionary response in the parasite’s virulence, we modelled the 
case of virulence evolution under an imperfect asexual stage malaria vaccine 
incorporating the feedbacks between the epidemiology (force of infection) and 
parasite evolution (Gandon et al., 2001). Parameter values were chosen to mimic an 
area of high year-round malaria transmission such as Tanzania.  As predicted, the 
parasite evolved higher virulence under vaccination so that the case fatality rate 
amongst unvaccinated naïve hosts was higher than if evolution had not occurred.   
Moreover, the total mortality across the whole population was also higher, especially 
when the vaccine was given to a moderate fraction of the population.  Thus all the 
expected benefits of vaccination were eroded by parasite evolution, and the situation 
was worse at intermediate levels of vaccine coverage (Fig. 7). 
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3.2.  Other types of vaccines and coinfection 
 
We also modelled other types of vaccines or devices that block infection (e.g., 
liver stage vaccines), or stop it transmitting from humans to mosquitoes (e.g., 
bednets), but that do not act directly on the asexual stage parasites and hence on the 
V-T-P relationships.  These control measures were predicted to have no impact, or as 
we explain below, could even lead to a decrease in virulence (Gandon et al., 2001).  
Thus, priority should be given to control measures that prevent pathogens from 
entering or leaving the host rather than measures that directly target the infection 
itself.  In malaria, the former would include bednets, vector control, and sporozoite 
and liver stage vaccines (unless they also reduce multiplication rates): the latter 
includes asexual-stage vaccines, anti-toxin vaccines and drug use.  Thus, in the face of 
a large potential for pathogen evolution, where possible, the hygiene principle would 
appear to be an excellent one to follow for evolutionary reasons as well as for its more 
obvious epidemiological applications. 
  The theoretical conclusion that using devices that prevent infection or block 
transmission will lead to reduced virulence arises because of the lower force of 
infection (transmission intensity from the vector population) caused by the control 
programme. This leads to lower levels of coinfection or superinfection and hence the 
lower level of competition among parasites occupying the same host.  The reduced 
selection pressure for high virulence due to relaxation of competition can be 
understood by taking the view of a resident parasite that is either ousted by 
(superinfection) or forced to share with (coinfection) another parasite type.  In the 
case of superinfection, the resident parasite has its infection shortened by the invading 
parasite: the parasite then compensates by evolving a higher level of host exploitation, 
or intrinsic virulence, up to the point when the benefits are balanced by the costs. This 
is especially so where virulence is associated with competitive ability, as it is at least 
in P. chabaudi (see section 2.1 above). In the case of coinfection, the risk of mortality 
for the resident parasite is increased by the presence of another parasite, thus 
increasing the costs.  Again, the parasite has to compensate by increasing its level of 
host exploitation (benefits).   
The principles of superinfection and coinfection also extend to co-morbidity 
from other infections. In malaria, concomitant infection with bacterial pathogens 
greatly enhances the probability of dying in young children (Berkley et al., 1999).  
This higher ‘background mortality’ in children is generally expected  to heighten the 
selection pressure on virulence (Lenski and May, 1994; Van Baalen and Sabelis, 
1995) (but see  Williams and Day, 2001). Thus controlling other diseases may also 
relieve the selection pressure on malaria virulence. Indeed, as discussed above, a 
general principle that arises from the trade-off model is that if external factors act to 
decrease the duration of infection, then optimum virulence increases.  These factors 
may be related to host death (e.g. war, co-morbidity, and mosquito mortality), or to 
the rate of clearance of the infection (e.g., superinfection, or drugs). 
   
 
4. An experimental test of the vaccination theory 
 
As we cannot test the vaccination hypothesis in the field until it is too late, we 
would ideally test it in the laboratory in mice or in vitro.  This could be done by 
evolving replicate parasite lines under conditions of high vs. low immunity using their 
natural transmission system.  However, it is extremely difficult in the laboratory to 
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repeatedly transmit multiple parasite lines of malaria through mosquitoes for the 
entire period of their transmissibility: it is also ethically challenging to allow mouse 
death to act as the selecting agent.  Therefore we designed an experiment to test one 
component of the vaccine hypothesis, namely, that immunity selects for higher rates 
of host exploitation (regardless of the transmission consequences).  This was done by 
transferring a standard number of parasites between mice every 7 days for 18 
passages, thus bypassing the mosquito stage of the life cycle.  At the end of this 
selection phase, the replicated lines were passaged once through mosquitoes and 
tested for virulence and other characteristics in either naïve or semi-immune mice.  
We found that parasite lines that had evolved in immunised hosts were more virulent 
than parasite lines that had evolved in naïve hosts (Fig. 8).  This was true whether the 
lines were infecting naïve or immunised mice, and whether or not the lines had been 
passaged through mosquitoes prior to testing them (Mackinnon and Read, 2004a).  
The immune-selected lines also had higher intrinsic replication rates than the naïve-
selected lines (Fig. 8).  Thus immunity had more efficiently selected the parasites with 
greater ability to exploit the host and thus cause more virulence.  This result is 
consistent with our theory that blood-stage vaccines would select for more virulent 
parasites, but the mechanism of selection in this experiment was different to that we 
proposed for human malaria in the field because we did not allow the mortality-
induced transmission costs to do the selecting. The results from this experiment 
nevertheless support the underlying basis of the trade-off model, namely, that 
replication rate is the parasite’s key to transmission success, especially in semi-
immune hosts, with virulence being an unfortunate side-effect.  
It will be impossible to do a direct test of the vaccination hypothesis in human 
malaria before the uncontrolled experiment is done on a vast scale.  But there are two 
approaches that could be taken in the meantime.  First, one could examine the 
outcome of the natural experiment that has been done.  According to the theory, 
parasites from highly immune populations (naturally acquired) should be intrinsically 
more virulent than parasites from less immune populations.  Thus a comparison of 
case fatality rates and disease severity among naïve individuals could be made from 
high transmission intensity areas (where population immunity is high) and from low 
transmission areas.  There is some limited evidence to support this argument  
(Murphy and Breman, 2001; Idro et al., 2006), but see Reyburn et al. (2005).  The 
hypothesis could also be tested by comparing mortality rates of malaria-naïve 
travellers who have acquired their infection from high vs. low transmission areas.   A 
second way would be to compare in vitro the virulence-related molecular phenotypes 
of parasites from areas with contrasting transmission intensities.  Studies taking both 
approaches are under way.  
  
5.   Vaccine-driven virulence evolution, and other diseases. 
One of the few large-scale malaria vaccine trials to date has already 
demonstrated vaccine-driven evolution (Genton et al. 2002). The Combination B 
asexual blood-stage vaccine consists of several blood stage antigens.  During a phase 
II trial in Papua New Guinea, it was shown that vaccination reduced the prevalence of 
the allele of one of the antigens used in the vaccine.  The alternative allele, which was 
not present in the vaccine and which rose in frequency, had in previous studies been 
associated with more virulent infections (Engelbrecht et al., 1995).   
In principle, a variety of different types of mutants could evolve in response to 
vaccination (Read and Mackinnon, 2007).  These could include antigenic variants that 
are less readily recognised by vaccine-induced immunity thus giving rise to ‘serotype 
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replacement’  (McLean, 1995; Gupta et al., 1997; Lipsitch, 1997).  However, there is 
no a priori reason to think such antigenic escape variants will have lower or higher 
intrinsic virulence than the one targeted by the vaccine.  In this paper, however, we 
have argued that there exist variants that have a fitness advantage in semi-immune 
hosts independent  of antigenic type, e.g., due to higher intrinsic growth rate.  In the 
absence of vaccination, these variants are selected against because of their excessive 
virulence in naïve hosts, but are favoured in vaccinated populations where they are 
protected from the fitness costs of host death.  Thus such escape variants could have 
changes at antigen loci, for instance where these affect replication rate, but they could 
also include loci other than those encoding antigens, such as genes encoding 
replication rate, toxin production, and immunosuppressive compounds, and these have 
the potential to confer great virulence.  For malaria, we do not have a clear idea which 
are the virulence genes, and therefore what the effects a particular vaccine might have 
on virulence evolution.  But our arguments above, combined with our experimental 
evolution results (Fig. 8) and the experience of the Combination B vaccine, suggest 
that we should consider in advance the possible evolutionary outcomes of imperfect 
interventions. 
Are there any examples in other pathogens where vaccines have driven the 
pathogen towards higher virulence? Vaccines against smallpox, measles and polio 
have been outstandingly successful.  These vaccines induce near-sterilising immunity. 
On the other hand, for diseases where vaccines are leaky, so that wild type pathogens 
transmit and thus evolve through immune people, changes in pathogen virulence 
following vaccination have been documented, such as diphtheria, pneumococcal 
disease and whooping cough (pertussis). These cases have been discussed in more 
detail elsewhere  (Read et al., 2004; Gandon and Day (this issue)). While these 
examples demonstrate that pathogen evolution in response to vaccines can happen, the 
effects on virulence are extremely difficult to determine because comparisons of 
virulence are very difficult without contemporaneous experimental infections with  
the different pathogen strains.   For many animal diseases, where such experiments 
can be done, successful vaccines are frequently leaky.  There are clear examples from 
the poultry industry of substantial increases in virulence following the widespread 
introduction of vaccines to both Marek’s disease and Infectious Bursal Disease 
(reviewed in Read et al., 2004).  These cases have all the hallmarks of vaccine-driven 
generalised virulence evolution.  However, experimental analysis of their V-T-P 
relationships is still required to determine whether vaccination was indeed the cause.  
The subsequent history of the myxoma virus evolution demonstrates the role host 
resistance can also play in driving virulence evolution.  As wild rabbits evolved 
greater resistance to myxomatosis, the virus evolved greater virulence (reviewed by  
Woolhouse et al., 2002; Read et al., 2004).  
Many new generation vaccines against human diseases are, like candidate 
malaria vaccines, very likely to be substantially leaky because natural immunity 
against their causative pathogens is far from perfect, or the pathogen has good 
mechanisms for immune evasion or suppression (e.g. HIV, Hepatitis B and C).  In 
diseases for which the V-T-P relationships are as they are in myxomatosis (Fig. 2) and 
rodent malaria (Fig. 3), we expect our argument to apply wherever imperfect vaccines 
are in widespread use.  For diseases where the V-T-P relationships are qualitatively 
different to those described above, vaccines could produce other evolutionary 
outcomes (e.g.,  Gandon et al., 2002). 
The current situation is, however, that for most human diseases we simply do 
not know the V-T-P relationships: indeed, in our view, much of the controversy 
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surrounding the trade-off model (Weiss, 2002; Ebert and Bull, 2003; Ganusov, 2003; 
Zimmer, 2003; Gandon and Day, 2003; Elliot, 2003) arises because of the lack of 
direct experimentation on medically-relevant diseases.  In the molecular era, it is now 
feasible for many disease systems to properly quantify pathogen transmission and 
persistence for individual infections for the range of circulating pathogen genotypes.  
Because of the variability in virulence and transmissibility during the infection, this is 
ideally done for the full course of the infection.  For example, of key importance is the 
time at which host mortality occurs in relation to when the bulk of transmission 
occurs.  If death occurs early in the infection (e.g., in malaria where transmission does 
not occur until after the most dangerous point in the infection), then loss of 
transmission is high and so the cost relative to the benefit is high: if it occurs late 
(e.g., in HIV or tuberculosis), much of the transmission has already occurred prior to 
host death, and the costs are relatively lower (Day, 2003).  Thus these diseases can 
“afford” higher mortality rates.  Such considerations, and others such as the role of 
immunity, and other in-host limitations in generating the trade-off curve (Antia et al., 
1994; Koella and Antia, 1995; Ganusov et al., 2002; André et al., 2003; Alizon and 
Van Baalen, 2005; Ganusov and Antia, 2006; André and Gandon, 2006), highlight the 
importance of understanding within-host dynamics to properly evaluate the V-T-P 
relationships in both acute and chronic infections.   This is an area we have so far paid 
little attention to in malaria, but we believe is one that is likely to be useful for 
properly quantifying the fitness benefits and costs of virulence in human malaria, and 
hence evaluating the applicability of the trade-off model to this disease. 
 
6. Conclusions 
 In the case of malaria, for which a vaccine is not yet available but is being 
intensively pursued, we have presented the case for why virulence may evolve in 
response to vaccines, what we might do to avoid it, and what we further need to do to 
determine its likelihood.  Key points are:  
• In rodent malaria, virulence, transmissibility and persistence appear to be 
intrinsically linked through the parasite’s biology/life history, and these links are 
maintained over different levels of host immunity.  We are unaware of any data on 
human malaria which contradicts this picture, though field and clinical data are 
necessarily more ambiguous.  Immunity has a very strong impact on parasite 
fitness through its effect on reducing all three V-T-P traits in accordance with their 
biological links, and by reducing host death and hence the fitness cost of 
virulence. 
• Our simple models, informed and parameterised from experimental work on 
rodent malaria and from human field data, predict that interventions that reduce 
asexual density but do not block infection, such as anti-asexual stage vaccines, 
and drugs, are expected to lead to evolution of higher virulence, while hygiene 
(i.e. preventing infection and transmission) is expected to lead to evolution of 
lower virulence.   
•  More data are required in human malaria to determine whether the V-T-P 
relationships are encoded by parasite genes, and to determine how much virulence 
variation exists in the field. Tests of the immunity-virulence evolution hypothesis 
in human malaria, where possible, are urgently required.  Better knowledge of the 
contributions to transmission by adults and children would help identify the most 
important source of selection pressure and hence help direct age-targeted 
interventions.   
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• Meanwhile, a cautionary approach to the widespread use of anti-replication or 
anti-disease vaccines seems justified.  Ideally, this means combining such 
vaccines with transmission-blocking vaccines, bednets, drugs, housing 
improvements and other transmission-reducing measures.  If a plurality of 
approaches is not possible, we urge long term monitoring of virulence trends, and 
the continual development of alternative anti-malarial measures.  The history of 
malaria control is one of continual failure in the face of evolution. 
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Fig. 1.  The costs and benefits of virulence (or, alternatively, high levels of host 
exploitation) to pathogen fitness. The fitness benefits associated with virulence are 
higher transmissibility and persistence (duration of infection). The fitness cost of 
virulence is host mortality which shortens the infection.  The rate of transmission and 
length of infection (which is determined by both persistence and the probability that 
the host dies) multiply together to give the total lifetime transmission of the pathogen 
from the host, i.e., its fitness.  This reaches a maximum at an intermediate level of 
virulence when the negative and positive effects on virulence are combined in this 
way.  Note that the transmissibility and duration of infection curves have to be less 
than linear (i.e., convex) in order to produce an intermediate optimum virulence. 
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Fig. 2.  Virulence evolution in myxomatosis.  A highly virulent myxomatosis virus 
was released into a rabbit population of Australia and Britain in the early 1950’s.  By 
the mid-1960’s, strains of the virus that were less virulent than the original were found 
to be circulating in the populations (graded I to V in decreasing order of virulence).  
The virulence of these strains showed positive, curvilinear relationships with 
infectivity to fleas/mosquitoes (Mead-Briggs and Vaughan, 1975) and the length of 
infection (Fenner and Ratcliffe, 1965) when measured in laboratory rabbits.  Using 
either of these relationships, and keeping the other one constant, gives maximum 
fitness at an intermediate level of virulence (Anderson and May, 1982; Massad, 
1987): this is also the case when both vary, as shown in the lower panel.  The 
predicted fitness function matches the distribution of strains observed in Australia 
after a decade (1959-1969) (Fenner, 1983)  where the most prevalent strains (grey 
bars) in the population were those of intermediate virulence, a situation which lasted 
for some time until the host evolved higher levels of resistance (Fenner and Fantini, 
1999; Best and Kerr, 2000).  Note that the very low infectivity of the highly virulent 
strain is not necessary to generate an intermediate virulence optimum: a 
transmissibility-virulence curve that had a horizontal asymptote  at 60% would too.  
Following Anderson and May (1982), assumed values of other parameters were a 
background mortality rate of 0.011/day and values of the daily transmission rate to 
uninfected rabbits approximately equal to infectivity, i.e., 0.1 to 0.6 transmissions per 
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Fig. 3.  Virulence-transmissibility-persistence relationships in the mouse model of 
malaria, P. chabaudi.  Each point is the average value of groups of mice (n = 5-10) 
infected with one parasite clone: thus a line fitted to the points would represent the 
parasite genetic relationship among the traits.  Filled symbols indicate naive mice and 
open symbols indicate mice made semi-immune by previous infection and drug 
clearance.  Virulence was measured as the mouse’s minimum red blood cell density 
reached during the infection.  It was shown to positively relate to transmissibility as 
measured by (a) daily average gametocyte density, and  (b) infectivity to mosquitoes 
on 2-4 days during the peak of gametocyte production.  (c) Recovery rate, which is 
inversely related to infection length, was measured as the rate at which the infection 
declined after peak parasitaemia and was negatively related to virulence, as expected.  
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(d) Virulence was positively related to maximum parasitaemia, an indicator of host 
exploitation.  Clones broadly retained their rankings for all traits when infecting naïve 
vs. immunised mice (Pearson correlations across treatments of 0.59-0.66 for the 4 
traits used here.)  In the experiments described in panels (a) to (d), very few mice died 
and so a virulence cost to transmission was not observable.  However, in another 
experiment using less resistant host genotypes, mortality was high (23%) and was 
shown to severely reduce the total number of gametocytes produced by the infection, 
shown in  (e).  Data were reproduced with permission from Mackinnon et al. (2002) 
and Mackinnon and Read (2003).  
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 Fig. 4.  Relationships between level of host exploitation, transmissibility, persistence 
and virulence (mortality) in human malaria in the field.  Data were taken from a 
longitudinal study in Nigeria in the 1970’s (the Garki Project,  Molineaux and 
Gramiccia, 1980).  Host exploitation is on the x-axis and is represented by average 
asexual parasite density. Each symbol represents an average for a group of people 
from the same age-group measured in 8 surveys, and decreases in size with age. (a) 
Transmissibility is represented by gametocyte density, and then converted to 
infectivity (dotted line, right axis) using logistic regression fitted to data from 
experimental mosquito infectivity data from the literature (data not shown).  (b) 
Persistence is represented by infection length estimated from consecutive 10-week 
surveys  (Bekessy et al., 1976) and adjusted for superinfections to lengths of 
individual infections using the method described by  Dietz et al., (1980). (c) All-cause 
mortality rates are shown as closed symbols: these are due to other factors as well as 
malaria, and include all the malaria infections that occur in a host per year, i.e., 
including superinfections.  The open symbols represent the values of mortality 
assuming that 25% of all deaths under the age of 9 years, and 1% in older categories, 
are due to malaria: these values are representative of studies where these proportions 
have been estimated, albeit with considerable uncertainty (Snow et al., 1999). 
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Fig. 5.  The expected amount of total transmission from hosts in different age-classes 
in the Garki project based on the data shown in Fig. 4 gives some indication of the 
parasite’s relative fitness in different host types.  Total transmission (black bars) was 
calculated as infectivity multiplied by vectorial capacity (the expected number of 
infectious bites to new hosts that result from a mosquito feeding on one host, infected 
or not, assumed to have a value of 8 here) divided by the expected infection length.  
Infection length here is the reciprocal of the sum of all-cause mortality rate (Fig. 4c) 
and recovery rate (inverse of individual infection length, Fig. 4b).  We use the length 
of an individual parasite infection in this calculation because we are interested in the 
relative transmission, or fitness, of an individual parasite strain rather than the total 
transmission from a group of coinfecting strains occupying the same host.  By 
contrast, mortality rate in this calculation is all-cause mortality because individual 
parasite genotypes suffer from the mortality caused by coinfecting parasites as well as 
that caused by themselves.  To illustrate the cost of host death on the parasite’s total 
lifetime productivity, we have performed the same calculation as above but assuming 
that malaria causes no mortality, i.e., the mortality rate is all-cause mortality reduced 
by 25% in children under 9 years (white bars).  The different-sized symbols above the 
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Fig. 6.  Immunity selects for higher levels of intrinsic virulence.  In (a), the solid line 
shows the fitness curve for parasites as a function of observed virulence in naïve 
hosts. In naïve hosts, it is maximised at some intermediate virulence level α
*
.  
However, if the parasite finds itself in a semi-immune host, its fitness is lower than 
maximal (vertical dotted line) because of its lower (by amount ∆) realised (or 
observed) virulence.  In (b), the fitness is shown as a function intrinsic virulence, i.e. 
that which would be observed in naïve hosts.  In semi-immune hosts (dotted line), 
fitness would be maximised at a virulence of α
*
+∆..  This is because its realised 
virulence would be this, less the effect of immunity, ∆.  But this optimal level of 
intrinsic virulence at α
*
+∆ would be too high for a naïve host (solid line), as indicated 
by the Nsymbol. 
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Fig. 7.  (a) Vaccines (or other control devices) can be targeted at different stages of 
the malaria parasite’s life cycle.  r1-type  devices block infection (e.g. a liver-stage 
vaccine), r2-type devices act against replication (e.g. asexual stage vaccines), r3-type 
devices act against transmission from the host (e.g. transmission-blocking vaccines or 
bednets), and r4-type devices act directly against the toxicity of the pathogen (e.g., 
anti-toxin vaccine, or life-saving therapies). (b) The consequences of virulence 
evolution to unvaccinated hosts (top panel) and the total population of hosts 
(vaccinated, unvaccinated and naturally immune) are shown as a function of vaccine 
coverage (x-axis).  The solid lines show the mortality expected if the pathogen 
evolves, and the dotted lines show the consequences if it does not.  For a r2-type 
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cause more death in unvaccinated individuals.  In contrast, r1-type and r3-type devices 
are expected to select for avirulence.  Preventing death using an r4-type device selects 
for higher virulence in unvaccinated people, but is beneficial to the overall population. 
The effect of a combination vaccine is shown in the last column. Reproduced with 
permission from  Gandon et al. (2001). 
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Fig. 8.  Results of serial passage of P. chabaudi through either immunised (I-lines) vs. 
naïve (N-lines) mice.  Starting with an avirulent clone, five independent parasite lines 
were blood-passaged in mice every 7 days for 18 passages (see Mackinnon and Read, 
2004a, for further details of the experimental design).   At the end, the lines were 
passaged through mosquitoes once, and then compared for their virulence (measured 
by the minimum blood cell density reached during the infection), the rate of 
population growth during the first 6 days using real-time PCR (see Mackinnon et al., 
2005 for details of methods), and rosetting frequency (the proportion of infected red 
blood cells cells that bind to more than two uninfected cells thus forming clusters, and 
the only molecular phenotype in human malaria that is consistently associated with 
virulence (Carlson et al., 1990; Treutiger et al., 1992; Ringwald et al., 1993; Rowe et 
al., 1995). Heights of bars represent means (with 95% confidence intervals) of groups 
of mice infected with the 5 selection lines per selection treatment.  Selection in 
immunised mice generated more virulent parasites than in naïve mice indicating that 
immunity selects more intensively for virulent forms during within-host selection.  
These differences were present in the lines both before (graphs on left) and after 
(right) mosquito transmission indicating that at least some of the evolved difference 
was genetically stable. These parasites also multiplied faster during the early, non-
growth-limiting stage of the infection before the onset of disease and a strong immune 
response.  This difference was not apparent in the lines before mosquito transmission, 
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al., 2005) having been reached.  Rosetting was also the same in the two sets of lines 
before mosquito transmission but different after transmission, and in the opposite 
direction to that expected from human malaria, i.e. it was lower in the most virulent 
lines.  Differences between pre-and post-mosquito transmission were significant for 
all three traits (virulence, P<0.05; multiplication rate, P<0.001; rosetting, P<0.05).  
Data in the top two figures are reproduced with permission from Mackinnon and Read 
(2004a). 
